WORK Medical Technology Group LTD WOK
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.04
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $9.8M | $11.5M | $13.6M | $19.7M | — |
| Gross profit | $2.3M | $2.9M | $4.1M | $4.4M | — |
| R&D | $435.3K | $302.5K | $301.6K | $183.9K | — |
| SG&A | $2.3M | $4.6M | $1.9M | $2.6M | — |
| Total operating expenses | $4.8M | $6.9M | $3.7M | $3.8M | — |
| Interest expense | $503.5K | $557.6K | $392.7K | $353.0K | — |
| Pre-tax income | -$1.1M | -$3.7M | $110.4K | $1.1M | — |
| Income tax | $119.1K | $125.3K | $47.0K | $169.4K | — |
| Net income | -$1.1M | -$3.5M | $112.0K | $865.2K | — |
| EPS, basic | -0.04 | -0.27 | 0.01 | 0.07 | — |
| EPS, diluted | -0.04 | -0.27 | 0.01 | 0.07 | — |
| Shares, diluted (wtd. avg.) | 29.0M | 12.7M | 12.5M | 12.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $4.1M | $6.6M | $1.6M | $773.4K | $873.1K |
| Receivables | $615.8K | $1.6M | $3.3M | — | — |
| Inventory | $2.5M | $3.2M | $4.6M | — | — |
| Total current assets | $20.5M | $20.8M | $22.2M | — | — |
| Property, plant and equipment | $10.6M | $11.4M | $6.6M | — | — |
| Other intangibles | $959.1K | $1.0M | $998.5K | — | — |
| Total assets | $33.2M | $36.3M | $30.0M | — | — |
| Accounts payable | $1.7M | $1.5M | $4.0M | — | — |
| Short-term debt | $6.4M | $13.3M | $8.8M | — | — |
| Total current liabilities | $12.0M | $20.2M | $18.9M | — | — |
| Total liabilities | $12.0M | $20.2M | $19.0M | — | — |
| Retained earnings | $5.0M | $6.1M | $9.6M | — | — |
| Total equity | $18.3M | $13.2M | $11.0M | $11.2M | $11.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | $6.2M | -$2.2M | $2.2M | -$2.3M | — |
| Depreciation and amortisation | $848.7K | $1.3M | $1.5M | $3.2M | — |
| Capital expenditure | $1.3M | $9.2M | $455.4K | $2.0M | — |
| Investing cash flow | -$7.6M | -$9.1M | -$583.3K | -$1.3M | — |
| Financing cash flow | -$898.2K | $15.7M | -$728.7K | $3.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-010301.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $19.7M | $13.6M | $11.5M | $9.8M |
| Gross profit | — | $4.4M | $4.1M | $2.9M | $2.3M |
| Net income | — | $865.2K | $112.0K | -$3.5M | -$1.1M |
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |